よむ、つかう、まなぶ。
【参考資料２－３】抗微生物薬適正使用の手引き 第四版（案）薬剤耐性菌感染症の抗菌薬適正使用編 (88 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
1
2
3
4
5
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
4. 引用文献
1.
Baddour LM, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy,
and Management of Complications: A Scientific Statement for Healthcare Professionals
From the American Heart Association. Circulation. 2015. 132(15):1435-1486.
6
7
2.
Cetinkaya Y, et al. Vancomycin-resistant enterococci. Clin Microbiol Rev. 2000.
13(4):686-707.
8
3.
抗菌薬生涯教育テキスト. 第 3 版 環状リポペプチド系抗菌薬 2020.
9
10
4.
Cairns KA, et al. Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream
Infections. Clin Microbiol Rev. 2023. 36(2):e0005922.
11
12
5.
Bennett JE, et al. Mandell, Douglas, and Bennett's principles and practice of infectious
diseases. 9th ed. Philadelphia: Elsevier. 2019.
13
14
15
6.
Shukla BS, et al. Influence of Minimum Inhibitory Concentration in Clinical Outcomes of
Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the
Breakpoint? Clin Infect Dis. 2016. 62(12):1514-1520.
16
17
18
7.
Harris PNA, et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality
for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone
Resistance: A Randomized Clinical Trial. JAMA. 2018. 320(10):984-994.
19
20
21
22
23
8.
Tamma PD, et al. Infectious Diseases Society of America 2023 Guidance on the
Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis. 2023.
18:ciad428. Tamma PD, et al. Infectious Diseases Society of America 2023 Guidance on
the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis. 2023.
18:ciad428.
24
25
26
9.
Henderson A, et al. Association Between Minimum Inhibitory Concentration, β-lactamase
Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem
From the MERINO Study. Clin Infect Dis. 2021. 73(11):e3842-e3850.
27
28
29
10. Matsumura Y, et al. Emergence and spread of B2-ST131-O25b, B2-ST131-O16 and DST405 clonal groups among extended-spectrum-β-lactamase-producing Escherichia coli
in Japan. J Antimicrob Chemother. 2012. 67(11):2612-2620.
30
31
32
11. Hayakawa K, et al. Effectiveness of cefmetazole versus meropenem for invasive urinary
tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Antimicrob Agents Chemother. 2023. 67(10):e0051023.
33
34
12. UMIN-CTR ホームページ. at https://center6.umin.ac.jp/cgi-openbin/ctr/ctr_view.cgi?recptno=R000055809.)
35
36
37
13. Matsumura Y, et al. In vitro activities and detection performances of cefmetazole and
flomoxef for extended-spectrum β-lactamase and plasmid-mediated AmpC β-lactamaseproducing Enterobacteriaceae. Diagn Microbiol Infect Dis. 2016. 84(4):322-327.
38
39
14. アンチバイオグラム作成ガイドライン, 感染症教育コンソーシアム, 2019. 2019. at
https://amr.ncgm.go.jp/pdf/201904_antibaiogram_guideline.pdf.
40
41
42
15. Lee NY, et al. Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia:
Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent
Isolates. Antimicrob Agents Chemother. 2015. 59(12):7558-7563.
88
1
2
3
4
5
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
4. 引用文献
1.
Baddour LM, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy,
and Management of Complications: A Scientific Statement for Healthcare Professionals
From the American Heart Association. Circulation. 2015. 132(15):1435-1486.
6
7
2.
Cetinkaya Y, et al. Vancomycin-resistant enterococci. Clin Microbiol Rev. 2000.
13(4):686-707.
8
3.
抗菌薬生涯教育テキスト. 第 3 版 環状リポペプチド系抗菌薬 2020.
9
10
4.
Cairns KA, et al. Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream
Infections. Clin Microbiol Rev. 2023. 36(2):e0005922.
11
12
5.
Bennett JE, et al. Mandell, Douglas, and Bennett's principles and practice of infectious
diseases. 9th ed. Philadelphia: Elsevier. 2019.
13
14
15
6.
Shukla BS, et al. Influence of Minimum Inhibitory Concentration in Clinical Outcomes of
Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the
Breakpoint? Clin Infect Dis. 2016. 62(12):1514-1520.
16
17
18
7.
Harris PNA, et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality
for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone
Resistance: A Randomized Clinical Trial. JAMA. 2018. 320(10):984-994.
19
20
21
22
23
8.
Tamma PD, et al. Infectious Diseases Society of America 2023 Guidance on the
Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis. 2023.
18:ciad428. Tamma PD, et al. Infectious Diseases Society of America 2023 Guidance on
the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis. 2023.
18:ciad428.
24
25
26
9.
Henderson A, et al. Association Between Minimum Inhibitory Concentration, β-lactamase
Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem
From the MERINO Study. Clin Infect Dis. 2021. 73(11):e3842-e3850.
27
28
29
10. Matsumura Y, et al. Emergence and spread of B2-ST131-O25b, B2-ST131-O16 and DST405 clonal groups among extended-spectrum-β-lactamase-producing Escherichia coli
in Japan. J Antimicrob Chemother. 2012. 67(11):2612-2620.
30
31
32
11. Hayakawa K, et al. Effectiveness of cefmetazole versus meropenem for invasive urinary
tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Antimicrob Agents Chemother. 2023. 67(10):e0051023.
33
34
12. UMIN-CTR ホームページ. at https://center6.umin.ac.jp/cgi-openbin/ctr/ctr_view.cgi?recptno=R000055809.)
35
36
37
13. Matsumura Y, et al. In vitro activities and detection performances of cefmetazole and
flomoxef for extended-spectrum β-lactamase and plasmid-mediated AmpC β-lactamaseproducing Enterobacteriaceae. Diagn Microbiol Infect Dis. 2016. 84(4):322-327.
38
39
14. アンチバイオグラム作成ガイドライン, 感染症教育コンソーシアム, 2019. 2019. at
https://amr.ncgm.go.jp/pdf/201904_antibaiogram_guideline.pdf.
40
41
42
15. Lee NY, et al. Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia:
Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent
Isolates. Antimicrob Agents Chemother. 2015. 59(12):7558-7563.
88